Hodgkin Lymphoma Clinical Trials

37 studies are recruiting for hodgkin lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

  1. A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

    To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    M D Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center
  2. Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

    This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    City of Hope, Duarte, California
    Locations
    7 in total
    Run by
    Marker Therapeutics, Inc.
  3. AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

    This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Research Site, Duarte, California
    Locations
    39 in total
    Run by
    AstraZeneca
  4. Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

    This is a phase 1 basket trial of TGFBR2 KO CAR27/IL-15 NK cells after lymphodepleting chemotherapy for patients with R/R B-NHL, HL, T-NHL or B-ALL.

    Stage
    Phase 1
    Ages
    18 to 75
    Site
    The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center
  5. Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

    The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult patients. The safety of this drug combination will also be studied.

    Stage
    Phase 2
    Ages
    2 to 21
    Site
    UT MD Anderson, Houston, Texas
    Run by
    M.D. Anderson Cancer Center
  6. Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma

    Pediatric patients receiving proton therapy for solid tumors or Hodgkin's lymphoma may experience anatomical changes during treatment that can affect proton therapy accuracy. This prospective single-arm study uses regular low-dose imaging to monitor these changes and adjust treatment plans as neede…

    Stage
    Not phased
    Ages
    Any age
    Site
    St. Jude Children's Research Hospital, Memphis, Tennessee
    Run by
    St. Jude Children's Research Hospital
  7. CD45BE-HSPC + CART-45 Cells

    This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor ce…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Pennsylvania, Philadelphia, Pennsylvania
    Run by
    University of Pennsylvania
  8. Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

    The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Miami, Miami, Florida
    Locations
    10 in total
    Run by
    Memorial Sloan Kettering Cancer Center
  9. Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

    The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells.…

    Stage
    Phase 1
    Ages
    12 to 80
    Site
    M D Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center
  10. ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

    Despite the progress in the therapy, Hodgkin's Lymphoma (HL) remains fatal for more than 15% of patients. Even in patients who are cured, the morbidity of therapy is substantial and long-lasting. New therapeutic agents are required therefore not only to further reduce mortality but also to alleviat…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
    Run by
    UNC Lineberger Comprehensive Cancer Center
  11. The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

    This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medica…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Mayo Clinic in Florida, Jacksonville, Florida
    Run by
    Mayo Clinic
  12. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

    This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Florida Cancer Specialists - Lake Nona, Orlando, Florida
    Locations
    10 in total
    Run by
    Compass Therapeutics
  13. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

    This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cel…

    Stage
    Phase 1
    Ages
    18 to 75
    Site
    City of Hope Medical Center, Duarte, California
    Locations
    3 in total
    Run by
    City of Hope Medical Center
  14. Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

    This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not responded to treatment. Previous research combined antibodies and T cells to t…

    Stage
    Phase 1
    Ages
    12 to 75
    Site
    Houston Methodist Hospital, Houston, Texas
    Locations
    2 in total
    Run by
    Baylor College of Medicine
  15. Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

    This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole bra…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California
    Run by
    University of California, Irvine
  16. Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

    RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials …

    Stage
    Phase 3
    Ages
    16 to 69
    Site
    Stanford University - (Stanford Cancer Institute), Stanford, California
    Locations
    72 in total
    Run by
    University College, London
  17. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

    This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

    Stage
    Not phased
    Ages
    Any age
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Locations
    142 in total
    Run by
    Center for International Blood and Marrow Transplant Research
  18. Familial Investigations of Childhood Cancer Predisposition

    NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor …

    Stage
    Not phased
    Ages
    Any age
    Site
    St. Jude Children's Research Hospital, Memphis, Tennessee
    Run by
    St. Jude Children's Research Hospital
  19. Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

    This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Minnesota, Minneapolis, Minnesota
    Locations
    6 in total
    Run by
    Veronika Bachanova
  20. Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma

    This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitn…

    Stage
    Not phased
    Ages
    10 to 25
    Site
    St. Jude Children's Research Hospital, Memphis, Tennessee
    Run by
    St. Jude Children's Research Hospital
  21. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

    The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

    Stage
    Not phased
    Ages
    0 to 38
    Site
    Children's Hospital Colorado, Aurora, Colorado
    Locations
    5 in total
    Run by
    Children's Hospital Medical Center, Cincinnati
  22. Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

    This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth …

    Stage
    Phase 2
    Ages
    0 and older
    Site
    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
    Run by
    Fred Hutchinson Cancer Center
  23. Cord Blood Transplantation in Children and Young Adults With Blood Cancer

    The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.

    Stage
    Phase 2
    Ages
    Up to 26
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Run by
    Memorial Sloan Kettering Cancer Center
  24. A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

    The purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage, bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatments for their disease. BV is a type of drug called an antibody-drug conjugate (ADC). ADCs are a subst…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey
    Locations
    8 in total
    Run by
    Memorial Sloan Kettering Cancer Center
  25. Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

    Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive…

    Stage
    Phase 1
    Ages
    12 to 70
    Site
    New York Medical Center, Valhalla, New York
    Run by
    New York Medical College

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.